Pressure control during preparation of saphenous veins
- PMID: 24759942
- PMCID: PMC4102634
- DOI: 10.1001/jamasurg.2013.5067
Pressure control during preparation of saphenous veins
Abstract
Importance: Long-term patency of human saphenous veins (HSVs) used as autologous conduits for coronary artery bypass grafting (CABG) procedures remains limited because of vein graft failure (VGF). Vein graft failure has been reported to be as high as 45% at 12 to 18 months after surgery and leads to additional surgery, myocardial infarction, recurrent angina, and death. Preparation of HSVs before implantation leads to conduit injury, which may promote VGF.
Objectives: To investigate whether pressure distension during vein graft preparation leads to endothelial injury and intimal thickening and whether limiting intraluminal pressure during pressure distension by using a pressure release valve (PRV) preserves endothelial function and prevents neointima thickening.
Design, setting, and participants: Segments of HSVs were collected in a university hospital from 13 patients undergoing CABG procedures immediately after harvest (unmanipulated [UM]), after pressure distension (after distension [AD]), and after typical intraoperative surgical graft preparation (after manipulation [AM]). Porcine saphenous veins (PSVs) from 7 healthy research animals were subjected to manual pressure distension with or without an in-line PRV that prevents pressures of 140 mm Hg or greater. Endothelial function of the HSVs and PSVs was determined in a muscle bath, endothelial integrity was assessed, and intimal thickening in PSVs was evaluated after 14 days in organ culture.
Main outcomes and measures: Endothelial function was measured in force, converted to stress, and defined as the percentage relaxation of maximal phenylephrine-induced contraction. Endothelial integrity was assessed by immunohistologic examination. Neointimal thickness was measured by histomorphometric analysis.
Results: Pressure distension of HSVs led to decreased mean (SEM) endothelial-dependent relaxation (5.3% [2.3%] for AD patients vs 13.7% [2.5%] for UM patients; P < .05) and denudation. In the AM group, the function of the conduits was further decreased (-3.2% [3.2%]; P < .05). Distension of the PSVs led to reduced endothelial-dependent relaxation (7.6% [4.4%] vs 61.9% [10.2%] in the control group; P < .05), denudation, and enhanced intimal thickening (15.0 [1.4] µm vs 2.2 [0.8] µm in the control group; P < .05). Distension with the PRV preserved endothelial-dependent relaxation (50.3% [9.6%]; P = .32 vs control), prevented denudation, and reduced intimal thickening (3.4 [0.8] µm; P = .56 vs controls) in PSVs.
Conclusions and relevance: Use of a PRV during graft preparation limits intraluminal pressure generated by manual distension, preserves endothelial integrity, and reduces intimal hyperplasia. Integration of this simple device may contribute to improved long-term vein graft patency.
Conflict of interest statement
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102634/bin/nihms549325f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102634/bin/nihms549325f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102634/bin/nihms549325f3.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102634/bin/nihms549325f4.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4102634/bin/nihms549325f5.gif)
Similar articles
-
Brilliant blue FCF as an alternative dye for saphenous vein graft marking: effect on conduit function.JAMA Surg. 2014 Nov;149(11):1176-81. doi: 10.1001/jamasurg.2014.2029. JAMA Surg. 2014. PMID: 25251505 Free PMC article.
-
Surgical vein graft preparation promotes cellular dysfunction, oxidative stress, and intimal hyperplasia in human saphenous vein.J Vasc Surg. 2014 Jul;60(1):202-11. doi: 10.1016/j.jvs.2013.06.004. Epub 2013 Jul 30. J Vasc Surg. 2014. PMID: 23911244 Free PMC article.
-
The impact of distension pressure on acute endothelial cell loss and neointimal proliferation in saphenous vein grafts.Eur J Cardiothorac Surg. 2012 Oct;42(4):e74-9. doi: 10.1093/ejcts/ezs402. Epub 2012 Aug 19. Eur J Cardiothorac Surg. 2012. PMID: 22906599
-
Structural and functional consequences of bypass grafting with autologous vein.Cryobiology. 1994 Feb;31(1):63-70. doi: 10.1006/cryo.1994.1008. Cryobiology. 1994. PMID: 8156801 Review.
-
Storage of saphenous vein grafts prior to coronary artery bypass grafting: is autologous whole blood more effective than saline in preserving graft function?Interact Cardiovasc Thorac Surg. 2012 Oct;15(4):720-5. doi: 10.1093/icvts/ivs275. Epub 2012 Jun 29. Interact Cardiovasc Thorac Surg. 2012. PMID: 22753436 Free PMC article. Review.
Cited by
-
Consensus statement-graft treatment in cardiovascular bypass graft surgery.Front Cardiovasc Med. 2024 Feb 27;11:1285685. doi: 10.3389/fcvm.2024.1285685. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 38476377 Free PMC article.
-
Impact of Age on Endothelial Function of Saphenous Vein Grafts in Coronary Artery Bypass Grafting.J Clin Med. 2023 Aug 22;12(17):5454. doi: 10.3390/jcm12175454. J Clin Med. 2023. PMID: 37685521 Free PMC article.
-
Impact of Graft Velocity on Saphenous Vein Graft Atherosclerosis after Coronary Artery Bypass Grafting.Ann Thorac Cardiovasc Surg. 2024 Jan 26;30(1):23-00066. doi: 10.5761/atcs.oa.23-00066. Epub 2023 Jul 19. Ann Thorac Cardiovasc Surg. 2024. PMID: 37468261 Free PMC article. Clinical Trial.
-
Influence of Three Different Surgical Techniques on Microscopic Damage of Saphenous Vein Grafts-A Randomized Study.Medicina (Kaunas). 2023 Jan 23;59(2):217. doi: 10.3390/medicina59020217. Medicina (Kaunas). 2023. PMID: 36837419 Free PMC article. Clinical Trial.
-
A novel Nanocellulose-Gelatin-AS-IV external stent resists EndMT by activating autophagy to prevent restenosis of grafts.Bioact Mater. 2022 Oct 25;22:466-481. doi: 10.1016/j.bioactmat.2022.10.013. eCollection 2023 Apr. Bioact Mater. 2022. PMID: 36330163 Free PMC article.
References
-
- Alexander JH, Hafley G, Harrington RA, et al. PREVENT IV Investigators. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294(19):2446–2454. - PubMed
-
- Conte MS, Bandyk DF, Clowes AW, et al. PREVENT III Investigators. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43(4):742–751. - PubMed
-
- Kouzi-Koliakos K, Kanellaki-Kyparissi M, Marinov G, et al. Prebypass histological and ultrastructural evaluation of the long saphenous vein as a predictor of early graft failure. Cardiovasc Pathol. 2006;15(6):336–346. - PubMed
-
- Conte MS. Technical factors in lower-extremity vein bypass surgery: how can we improve outcomes? Semin Vasc Surg. 2009;22(4):227–233. - PubMed
-
- LoGerfo FW, Haudenschild CC, Quist WC. A clinical technique for prevention of spasm and preservation of endothelium in saphenous vein grafts. Arch Surg. 1984;119(10):1212–1214. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical